Stressing the Ubiquitin-Proteasome System without 20S Proteolytic Inhibition Selectively Kills Cervical Cancer Cells

Cervical cancer cells exhibit an increased requirement for ubiquitin-dependent protein degradation associated with an elevated metabolic turnover rate, and for specific signaling pathways, notably HPV E6-targeted degradation of p53 and PDZ proteins. Natural compounds with antioxidant properties including flavonoids and triterpenoids hold promise as anticancer agents by interfering with ubiquitin-dependent protein degradation. An increasing body of evidence indicates that their α-β unsaturated carbonyl system is the molecular determinant for inhibition of ubiquitin-mediated protein degradation up-stream of the catalytic sites of the 20S proteasome. Herein we report the identification and characterization of a new class of chalcone-based, potent and cell permeable chemical inhibitors of ubiquitin-dependent protein degradation, and a lead compound RAMB1. RAMB1 inhibits ubiquitin-dependent protein degradation without compromising the catalytic activities of the 20S proteasome, a mechanism distinct from that of Bortezomib. Treatment of cervical cancer cells with RAMB1 triggers unfolded protein responses, including aggresome formation and Hsp90 stabilization, and increases p53 steady state levels. RAMB1 treatment results in activation of lysosomal-dependent degradation pathways as a mechanism to compensate for increasing levels of poly-ubiquitin enriched toxic aggregates. Importantly, RAMB1 synergistically triggers cell death of cervical cancer cells when combined with the lysosome inhibitor Chloroquine.

• Publication year

  2011

• Venue

  PLoS ONE

• Publication date

  2011-08-31

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1371/journal.pone.0023888PMID 21909374PMCID 3166081
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• α,β-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells.

  2011cited by this paper
• Resveratrol induces SIRT1- and energy–stress-independent inhibition of tumor cell regrowth after low-dose platinum treatment

  2011cited by this paper
• Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.

  2011cited by this paper
• Licochalcone A inhibits growth of gastric cancer cells by arresting cell cycle progression and inducing apoptosis.

  2011cited by this paper
• Green tea polyphenols as proteasome inhibitors: implication in chemoprevention.

  2011cited by this paper
• Abrogation of Akt signaling by Isobavachalcone contributes to its anti-proliferative effects towards human cancer cells.

  2010cited by this paper
• Systemic Administration of Polymeric Nanoparticle-Encapsulated Curcumin (NanoCurc) Blocks Tumor Growth and Metastases in Preclinical Models of Pancreatic Cancer

  2010cited by this paper
• The therapeutic potential of deubiquitinating enzyme inhibitors.

  2010cited by this paper
• Vitamin A Enhances Antitumor Effect of a Green Tea Polyphenol on Melanoma by Upregulating the Polyphenol Sensing Molecule 67-kDa Laminin Receptor

  2010cited by this paper
• Resveratrol Enhances Antitumor Activity of TRAIL in Prostate Cancer Xenografts through Activation of FOXO Transcription Factor

  2010cited by this paper
• Therapeutically targeting the SUMOylation, Ubiquitination and Proteasome pathways as a novel anticancer strategy

  2010cited by this paper
• Cyclin D1 degradation is sufficient to induce G1 cell cycle arrest despite constitutive expression of cyclin E2 in ovarian cancer cells.

  2009cited by this paper
• Curcumin induces apoptosis-independent death in oesophageal cancer cells

  2009cited by this paper
• N-terminal-prolonged vinyl ester-based peptides as selective proteasome beta1 subunit inhibitors.

  2009cited by this paper
• Combination of Proteasome and HDAC Inhibitors for Uterine Cervical Cancer Treatment

  2009cited by this paper
• Ubiquitin Proteasome System Stress Underlies Synergistic Killing of Ovarian Cancer Cells by Bortezomib and a Novel HDAC6 Inhibitor

  2008influential reference
• Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo.

  2008cited by this paper
• Natural compounds with proteasome inhibitory activity for cancer prevention and treatment.

  2008cited by this paper
• Targeting ubiquitin specific proteases for drug discovery.

  2008cited by this paper
• Green tea polyphenols reverse cooperation between c-Rel and CK2 that induces the aryl hydrocarbon receptor, slug, and an invasive phenotype.

  2007cited by this paper
• Activation of FOXO3a by the green tea polyphenol epigallocatechin-3-gallate induces estrogen receptor alpha expression reversing invasive phenotype of breast cancer cells.

  2007cited by this paper
• Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate.

  2006cited by this paper
• Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis.

  2006cited by this paper
• Activity profiling of deubiquitinating enzymes in cervical carcinoma biopsies and cell lines

  2006cited by this paper
• E3 ubiquitin ligases as cancer targets and biomarkers.

  2006cited by this paper
• Clonogenic assay of cells in vitro

  2006cited by this paper
• Celastrol, a triterpene extracted from the Chinese "Thunder of God Vine," is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice.

  2006cited by this paper
• The burden of HPV-related cancers

  2006cited by this paper
• A Boronic-Chalcone Derivative Exhibits Potent Anticancer Activity through Inhibition of the Proteasome

  2006cited by this paper
• Chapter 2: The burden of HPV-related cancers.

  2006cited by this paper
• Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.

  2006cited by this paper
• Punaglandins, chlorinated prostaglandins, function as potent Michael receptors to inhibit ubiquitin isopeptidase activity.

  2004cited by this paper
• Repression of the Human Papillomavirus E6 Gene Initiates p53-Dependent, Telomerase-Independent Senescence and Apoptosis in HeLa Cervical Carcinoma Cells

  2004cited by this paper
• p53 Represses Cyclin D1 Transcription through Down Regulation of Bcl-3 and Inducing Increased Association of the p52 NF-κB Subunit with Histone Deacetylase 1

  2003cited by this paper
• Imaging 26S proteasome activity and inhibition in living mice

  2003cited by this paper
• Cyclopentenone Prostaglandins of the J Series Inhibit the Ubiquitin Isopeptidase Activity of the Proteasome Pathway*

  2001cited by this paper
• Complete switch from Mdm2 to human papillomavirus E6-mediated degradation of p53 in cervical cancer cells.

  2001cited by this paper
• Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

  1999cited by this paper
• The ubiquitin-proteasome proteolytic pathway.

  1994cited by this paper
• The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53.

  1993cited by this paper
• HPV16 E6 and E7 proteins cooperate to immortalize human foreskin keratinocytes.

  1989cited by this paper
• Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors.

  1984influential reference

• Palmitoylethanolamide, an endogenous fatty acid amide, and its pleiotropic health benefits: A narrative review

  2024cites this paper
• Clinical Spectrum of USP8 Pathogenic Variants in Cushing's Disease.

  2023cites this paper
• Molecular and biological functions of gingerol as a natural effective therapeutic drug for cervical cancer

  2021cites this paper
• Ubiquitin–proteasome system and the role of its inhibitors in cancer therapy

  2021cites this paper
• Chalcones as Promising Antitumor Agents by Targeting the p53 Pathway: An Overview and New Insights in Drug-Likeness

  2021cites this paper
• Dienone Compounds: Targets and Pharmacological Responses

  2020cites this paper
• Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers

  2020cites this paper
• GSK3β is a key regulator of the ROS-dependent necrotic death induced by the quinone DMNQ

  2020cites this paper
• Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties

  2020cites this paper
• INTERNATIONAL JOURNAL OF NOVEL TRENDS IN PHARMACEUTICAL SCIENCES

  2020cites this paper
• Physical and Functional Analysis of the Putative Rpn13 Inhibitor RA190.

  2020cites this paper
• Small‐Molecule Inhibitors of the Proteasome's Regulatory Particle

  2019cites this paper
• RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment

  2018cites this paper
• UNC-45A Is a Novel Microtubule-Associated Protein and Regulator of Paclitaxel Sensitivity in Ovarian Cancer Cells

  2018cites this paper
• Effects of shRNA‐mediated silencing of PSMA7 on cell proliferation and vascular endothelial growth factor expression via the ubiquitin‐proteasome pathway in cervical cancer

  2018cites this paper
• The roles of ubiquitin modifying enzymes in neoplastic disease.

  2017cites this paper
• Proteases in Physiology and Pathology

  2017cites this paper
• Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors

  2017cites this paper
• Functional Relevance of Deubiquitinases in Life and Disease

  2017cites this paper
• Molecular Pathology of Cervical Dysplasia and Carcinoma

  2017cites this paper
• USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment

  2016cites this paper
• Deubiquitinases and cancer: A snapshot

  2016cites this paper
• The Characterization of the Novel Chloroquine Derivative VR23 for its Anticancer Properties

  2015cites this paper
• Deubiquitinase inhibition as a cancer therapeutic strategy.

  2015cites this paper
• Simultaneous inhibition of deubiquitinating enzymes (DUBs) and autophagy synergistically kills breast cancer cells

  2015cites this paper
• Inhibition of proteasome deubiquitinase activity: a strategy to overcome resistance to conventional proteasome inhibitors?

  2015cites this paper
• Chalcones as Promising Lead Compounds on Cancer Therapy.

  2015cites this paper
• Proteasome inhibition mediates p53 reactivation and anti-cancer activity of 6-Gingerol in cervical cancer cells

  2015cites this paper
• Measurement of deubiquitinating enzyme activity via a suicidal HA-Ub-VS probe.

  2015cites this paper
• A reversible and highly selective inhibitor of the proteasomal ubiquitin receptor rpn13 is toxic to multiple myeloma cells.

  2015cites this paper
• Small-Molecule RA-9 Inhibits Proteasome-Associated DUBs and Ovarian Cancer In Vitro and In Vivo via Exacerbating Unfolded Protein Responses

  2014cites this paper
• Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis

  2014cites this paper
• Emerging Biological Treatments for Uterine Cervical

  2014cites this paper
• New use for old drugs? Prospective targets of chloroquines in cancer therapy.

  2014cites this paper
• Emerging Biological Treatments for Uterine Cervical Carcinoma

  2014cites this paper
• Molecular targeted approaches to cancer therapy and prevention using chalcones.

  2014cites this paper
• A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer.

  2013cites this paper
• The role of human papillomavirus in nongenital cancers

  2013cites this paper
• A novel bullet hits the proteasome.

  2013cites this paper
• Erratum to Issaenko OA, et al. Cell Cycle Volume 11, Issue 9; pp. 1804-17.

  2012cites this paper
• HPV16 activates the promoter of Oct4 gene by sequestering HDAC1 from repressor complex to target it to proteasomal degradation.

  2012cites this paper
• Proteasome and cancer.

  2012cites this paper
• New promising molecular targets in head and neck squamous cell carcinoma

  2012cites this paper
• , an endogenous fatty acid amide, and its pleiotropic health benefits: A narrative review

  year unknowncites this paper